Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Alice Wong and Dr Joseph Stramondo join us on this special episode of Ethics Talk to discuss how perspectives from the disability community can help us think more powerfully about quality of life, resource allocation, and other ethical challenges arising in pandemics. Transcript available.
One patient’s experience of life-encompassing iatrogenic harm from being institutionalized emphasizes Italy’s comparative success, relative to the United States, in recovering from decades of deinstitutionalization policy.
AMA J Ethics. 2022;24(8):E795-803. doi:
10.1001/amajethics.2022.795.
This article examines conceptual limitations of extant accounts of palliative psychiatry, with a focus on obligations to distinguish among and clearly formulate goals of care.
AMA J Ethics. 2023;25(9):E710-717. doi:
10.1001/amajethics.2023.710.
Antimicrobial resistance demonstrates the fruitfulness of public health and bioethics collaborations by applying key concepts of interconnection and interdependence.
AMA J Ethics. 2024;26(2):E162-170. doi:
10.1001/amajethics.2024.162.